Literature DB >> 19470380

Rescue of alpha-synuclein cytotoxicity by insulin-like growth factors.

Shyan-Yuan Kao1.   

Abstract

While mutation of alpha-synuclein is a cause of autosomal-dominant Parkinson's disease (PD), it is still elusive as to how alpha-synuclein is involved in the pathogenesis of PD. Here, we show that dopamine-dependent accumulation of alpha-synuclein in cultured cells results in apoptosis. Furthermore, activation of insulin-like growth factor 1 (IGF-1) pathway can rescue alpha-synuclein toxicity and suppress alpha-synuclein aggregation through the activation of PI3K/Akt pathways. These results suggest the therapeutic potential of IGF-1 pathway in Parkinson disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19470380     DOI: 10.1016/j.bbrc.2009.05.089

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  18 in total

1.  Akt as a victim, villain and potential hero in Parkinson's disease pathophysiology and treatment.

Authors:  Lloyd A Greene; Oren Levy; Cristina Malagelada
Journal:  Cell Mol Neurobiol       Date:  2011-03-10       Impact factor: 5.046

Review 2.  Dysregulation of IGF-1/GLP-1 signaling in the progression of ALS: potential target activators and influences on neurological dysfunctions.

Authors:  Ambika Shandilya; Sidharth Mehan
Journal:  Neurol Sci       Date:  2021-05-21       Impact factor: 3.307

Review 3.  Gut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutide.

Authors:  Emanuel Monteiro Candeias; Inês Carolina Sebastião; Susana Maria Cardoso; Sónia Catarina Correia; Cristina Isabel Carvalho; Ana Isabel Plácido; Maria Sancha Santos; Catarina Resende Oliveira; Paula Isabel Moreira; Ana Isabel Duarte
Journal:  World J Diabetes       Date:  2015-06-25

4.  Activation of IGF-1/GLP-1 Signalling via 4-Hydroxyisoleucine Prevents Motor Neuron Impairments in Experimental ALS-Rats Exposed to Methylmercury-Induced Neurotoxicity.

Authors:  Ambika Shandilya; Sidharth Mehan; Sumit Kumar; Pranshul Sethi; Acharan S Narula; Abdulrahman Alshammari; Metab Alharbi; Abdullah F Alasmari
Journal:  Molecules       Date:  2022-06-16       Impact factor: 4.927

Review 5.  The role of NURR1 in metabolic abnormalities of Parkinson's disease.

Authors:  Murad Al-Nusaif; Yuting Yang; Song Li; Cheng Cheng; Weidong Le
Journal:  Mol Neurodegener       Date:  2022-06-27       Impact factor: 18.879

6.  Crosstalk between insulin-like growth factor-1 and angiotensin-II in dopaminergic neurons and glial cells: role in neuroinflammation and aging.

Authors:  Ana I Rodriguez-Perez; Ana Borrajo; Carmen Diaz-Ruiz; Pablo Garrido-Gil; Jose L Labandeira-Garcia
Journal:  Oncotarget       Date:  2016-05-24

7.  Serum IGF-1 is associated with cognitive functions in early, drug-naïve Parkinson's disease.

Authors:  Marina Picillo; Rosario Pivonello; Gabriella Santangelo; Claudia Pivonello; Riccardo Savastano; Renata Auriemma; Marianna Amboni; Sara Scannapieco; Angela Pierro; Annamaria Colao; Paolo Barone; Maria Teresa Pellecchia
Journal:  PLoS One       Date:  2017-10-24       Impact factor: 3.240

Review 8.  The Role of Insulin/IGF-1/PI3K/Akt/GSK3β Signaling in Parkinson's Disease Dementia.

Authors:  Liying Yang; Hongyan Wang; Lijun Liu; Anmu Xie
Journal:  Front Neurosci       Date:  2018-02-20       Impact factor: 4.677

9.  The intracellular angiotensin system buffers deleterious effects of the extracellular paracrine system.

Authors:  Begoña Villar-Cheda; Maria A Costa-Besada; Rita Valenzuela; Emma Perez-Costas; Miguel Melendez-Ferro; Jose L Labandeira-Garcia
Journal:  Cell Death Dis       Date:  2017-09-07       Impact factor: 8.469

10.  New hope for devastating neurodegenerative disease.

Authors:  Sandy Stayte; Bryce Vissel
Journal:  Brain       Date:  2017-05-01       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.